Research programme: antibody drug conjugates - ADC Therapeutics

Drug Profile

Research programme: antibody drug conjugates - ADC Therapeutics

Alternative Names: ADCT 501; ADCT 601

Latest Information Update: 01 Mar 2017

Price : $50

At a glance

  • Originator ADC Therapeutics; Cancer Research Technology
  • Class Immunoconjugates
  • Mechanism of Action DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Multiple myeloma

Most Recent Events

  • 05 Jan 2017 Preclinical trials in Multiple myeloma in United Kingdom (Parenteral)
  • 29 Nov 2016 Pharmacodynamics data from preclinical studies in Cancer presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR- 2016)
  • 20 Oct 2016 ADC Therapeutics in-licenses GlycoConnect and HydraSpace technology from Synaffix
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top